Eli Lilly’s Zepbound, an injectable prescription weight loss medication containing Tirzepatide, is clinically proven to lead to a substantial reduction of body weight.
Compounded Tirzepatide (cTirzepatide) has grown in popularity due to the limited availability of Zepbound which has been on the FDA’s shortage list for months.
This opened an opportunity for pharmacies, IV infusion clinics, telehealth entrepreneurs and medical spas to fill the gap by producing cTirzepatide, “essentially a copy” of its commercial counterpart for a fraction of the cost.
In this article, we will outline the differences between cTirzepatide and Zepbound.